IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of “Buy” by Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been given a consensus rating of “Buy” by the twenty analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $241.79.

IQV has been the topic of several research reports. Jefferies Financial Group increased their price target on shares of IQVIA from $259.00 to $273.00 and gave the stock a “buy” rating in a report on Friday, April 23rd. Canaccord Genuity upped their price objective on IQVIA from $220.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, May 12th. Robert W. Baird upped their price objective on IQVIA from $238.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, April 23rd. They noted that the move was a valuation call. Mizuho upped their price objective on IQVIA from $218.00 to $250.00 and gave the stock a “buy” rating in a research report on Friday, April 23rd. Finally, Stephens upgraded IQVIA from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $180.00 to $250.00 in a research report on Friday, April 16th.

Shares of NYSE:IQV opened at $242.80 on Friday. IQVIA has a twelve month low of $133.18 and a twelve month high of $244.95. The stock has a 50 day simple moving average of $227.58. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 1.94. The firm has a market cap of $46.54 billion, a P/E ratio of 115.62, a PEG ratio of 2.23 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, April 22nd. The medical research company reported $2.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.85 by $0.33. IQVIA had a net margin of 3.40% and a return on equity of 20.96%. The company had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the prior year, the company earned $1.50 EPS. IQVIA’s quarterly revenue was up 23.8% on a year-over-year basis. On average, research analysts anticipate that IQVIA will post 8.15 EPS for the current year.

Several large investors have recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. lifted its holdings in IQVIA by 4.5% in the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 1,066 shares of the medical research company’s stock valued at $206,000 after purchasing an additional 46 shares in the last quarter. Capital Analysts LLC lifted its holdings in IQVIA by 8.6% in the 1st quarter. Capital Analysts LLC now owns 596 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares in the last quarter. ProVise Management Group LLC lifted its holdings in IQVIA by 0.9% in the 1st quarter. ProVise Management Group LLC now owns 5,676 shares of the medical research company’s stock valued at $1,096,000 after purchasing an additional 50 shares in the last quarter. IFP Advisors Inc lifted its holdings in IQVIA by 2.0% in the 1st quarter. IFP Advisors Inc now owns 2,751 shares of the medical research company’s stock valued at $536,000 after purchasing an additional 54 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in IQVIA by 0.4% in the 4th quarter. Cerity Partners LLC now owns 15,717 shares of the medical research company’s stock valued at $2,816,000 after purchasing an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 87.02% of the company’s stock.

About IQVIA

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Why do companies engage in swaps?

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.